Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized trial of filgotinib in active ankylosing spondylitis
2016-003636-21Phase 2Completed
- Sponsor
- Galapagos NV
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ankylosing spondylitis (AS) comparing Filgotinib with Placebo (2 arms). Primary endpoint: Change from baseline in ASDAS at Week 12. Started Dec 2016; status: completed.
02
Drugs
filgotinib
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on 2016-003636-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003636-21.